Across TCGA pan-cancer cohorts, EXOSC8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EXOSC8 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher EXOSC8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXOSC8 expression acts as an unfavorable survival marker.
SKCM and BRCA are the cancer types where EXOSC8 Mutation most reproducibly stratifies survival.